Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605529 | 0.84 | F2 (0.42) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL6608002 | 0.81 | SLC6A2 (0.34) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL6603880 | 0.80 | PDE4A (0.32) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL7454055 | 0.80 | SLC6A2 (0.33) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL6606725 | 0.79 | PDE4D (0.36) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL7454053 | 0.79 | SLC6A2 (0.33) | PDE4DPDE4BPDE4APDE4CHTR6 | |
| SCHEMBL31482697 | 0.77 | PDE4D (0.42) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL6604822 | 0.75 | PDE4A (0.34) | PDE4DPDE4BPDE4APDE4CF2 | |
| SCHEMBL31482723 | 0.71 | PDE4D (0.47) | PDE4DPDE4B | |
| SCHEMBL7017070 | 0.71 | PDE4A (0.54) | PDE4DPDE4BPDE4APDE4CF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257548-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1257548-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 2002-11-20 | — | — | EP | disclosed |
| US-6455561-B1 | ADMINISTERING BENZOFURAN DERIVATIVE FOR THERAPY OF DISEASE STATE THAT IS CAPABLE OF BEING MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2002-09-24 | — | — | US | disclosed |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-02-21 | — | — | US | disclosed |
| US-6331556-B2 | BENZOFURAN-4-CARBOXYLIC ACID AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITORS | DARWIN DISCOVERY, LTD. (GB) | 2001-12-18 | — | — | US | disclosed |
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| WO-2001058895-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031777-A1 | Heterocyclic compounds and their therapeutic use | CYP2F1, CYP11B2, CYP3A7 | PDE4D 3103/4885PDE4B 2238/4885PDE4A 3177/4885 |
| US-20020022645-A1 | Heterocyclic compounds and their therapeutic use | EPX, MPO, PDE3B | PDE4D 34/4885PDE4B 8/4885PDE4A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.